MSU-ICH is a prospective, multicenter, Week-wise-randomized, open-label, blinded-endpoint (PROBE) clinical trial comparing ultra-early prehospital blood pressure lowering delivered by a Mobile Stroke Unit (MSU) with standard Emergency Medical Services (EMS) in patients with spontaneous intracerebral hemorrhage.
History and physical/neurological examination consistent with acute stroke.
Age ≥18 years;
Time from symptom onset to enrollment <3 hours (onset defined as last known normal).
Systolic blood pressure ≥150 mmHg and ≤220 mmHg;
Glasgow Coma Scale (GCS) score ≤5.
Contraindications to intensive blood pressure lowering, including severe arterial stenosis or high-grade stenotic valvular heart disease.
Malignant disease or other serious primary illness with a life expectancy of <3 months.
Current participation in another interventional randomized clinical trial.
Xuanwu Hospital, Beijing
Lead sponsor
Beijing Emergency Medical Center
Collaborator
Huizhou Third People's Hospital, Guangzhou Medical University
Collaborator
Suzhou First People's Hospital
Collaborator
Nanyang nanshi Hospital
Collaborator